Get the Stockscreener App
0.7801
14.75%
0.1003
After Hours:
.78
-0.000100
-0.01%
Citius Oncology Inc stock is traded at $0.7801, with a volume of 212.77K.
It is up +14.75% in the last 24 hours and down -3.98% over the past month.
Citius Oncology Inc is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.The Company centers on achieving a market position by advancing therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies. The company focused on key geographies and stakeholders, majorly on cancer centers and patients.
See More
Previous Close:
$0.6798
Open:
$0.69
24h Volume:
212.77K
Relative Volume:
0.82
Market Cap:
$68.86M
Revenue:
-
Net Income/Loss:
$-23.64M
P/E Ratio:
-2.532
EPS:
-0.3081
Net Cash Flow:
$-12.89M
1W Performance:
+17.50%
1M Performance:
-3.98%
6M Performance:
-54.11%
1Y Performance:
+17.52%
1-Day Range:
$0.6899
$0.785
1-Week Range:
$0.6161
$0.785
52-Week Range:
$0.4912
$6.19
Citius Oncology Inc Stock (CTOR) Company Profile
Name
Citius Oncology Inc
Sector
Phone
(908) 967-6677
Address
11 COMMERCE DRIVE, CRANFORD
Compare CTOR vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTOR
Citius Oncology Inc
|
0.7801 | 59.59M | 0 | -23.64M | -12.89M | -0.3081 |
TAK
Takeda Pharmaceutical Co Adr
|
17.85 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
121.11 | 49.56B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.70 | 43.86B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.77 | 35.89B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
578.54 | 25.06B | 3.18B | 1.33B | 1.04B | 27.90 |
Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-23-25 | Upgrade | Maxim Group | Hold → Buy |
| Nov-27-24 | Initiated | Maxim Group | Buy |
Citius Oncology Inc Stock (CTOR) Latest News
Aug Retail: Can Citius Oncology Inc lead its sector in growth2026 Dividend Review & AI Driven Stock Price Forecasts - baoquankhu1.vn
Citius Oncology Inc. (CTOR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
CTXR Stock Price, Quote & Chart | CITIUS PHARMACEUTICALS INC (NASDAQ:CTXR) - ChartMill
Citius Oncology reports 86% response rate in lymphoma study By Investing.com - Investing.com India
CTOR Stock Price, Quote & Chart | CITIUS ONCOLOGY INC (NASDAQ:CTOR) - chartmill.com
Citius Oncology reports early adoption metrics for lymphoma drug By Investing.com - Investing.com South Africa
Citius Oncology highlights early LYMPHIR commercial traction, expansion - TipRanks
Citius Oncology advances LYMPHIR launch and global expansion - TipRanks
Citius Oncology reports strong early LYMPHIR launch with broad payer coverage and institutional uptake - TradingView — Track All Markets
Citius Oncology reports early adoption metrics for lymphoma drug - Investing.com
Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development - PR Newswire
Can Citius Oncology Inc keep up with sector leaders2026 Pullbacks & Risk Managed Investment Entry Signals - baoquankhu1.vn
Aug PreEarnings: Should you avoid Sionna Therapeutics Inc stock right now2026 Catalysts & High Conviction Buy Zone Picks - baoquankhu1.vn
Institution Moves: Can Citius Oncology Inc lead its sector in growthTrade Exit Summary & Fast Gain Stock Tips - baoquankhu1.vn
Citius Oncology to Participate in USCLC Annual Workshop 2026, Hi - GuruFocus
Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts - Nasdaq
Citius Oncology (NASDAQ:CTOR) Trading Down 2.8%Here's What Happened - MarketBeat
Citius Oncology (CTOR) expands Lymphir distribution to Europe through exclusive agreement with Uniphar - MSN
If You Invested $1,000 in Citius Pharmaceuticals Inc (CTXR) - Stock Titan
Citius Oncology inks exclusive European distribution pact with Uniphar - MSN
Citius Oncology, Inc.: Fundamental Analysis and Financial Ratings | CTOR | US17331Y1091 - marketscreener.com
Activity Recap: Will Citius Oncology Inc outperform small cap indexes2026 Opening Moves & Safe Entry Trade Reports - baoquankhu1.vn
CTORCitius Oncology, Inc. Latest Stock News & Market Updates - Stock Titan
CTOR Stock Price and Chart — NASDAQ:CTOR - TradingView — Track All Markets
Analysts Offer Insights on Healthcare Companies: Citius Oncology (CTOR) and Oruka Therapeutics (ORKA) - The Globe and Mail
Citius Oncology reports positive phase 1 trial data for LYMPHIR By Investing.com - Investing.com Nigeria
Citius Oncology reports positive phase 1 trial data for LYMPHIR - Investing.com Australia
Citius Highlights Positive LYMPHIR Phase 1 Gynecologic Cancer Data - TipRanks
Citius Oncology Reports Positive Phase 1 LYMPHIR Combination Data - TipRanks
Citius reports positive Phase 1 topline: 24% ORR, 48% CBR for LYMPHIR + pembrolizumab in gynecologic cancers - TradingView
Citius Oncology Announces Positive Topline Results from Investig - GuruFocus
Citius Oncology, Inc. Announces Positive Topline Results from Investigator-Initiated Phase 1 Study of Lymphir in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers - marketscreener.com
Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers - PR Newswire
Aug EndMonth: Can Citius Oncology Inc lead its sector in growthPortfolio Risk Summary & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Aug Highlights: Does Citius Oncology Inc have strong fundamentalsMarket Risk Analysis & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
Citius Pharma (CTXR) Becomes Revenue-Generating With the Commercial Launch of LYMPHIR - Finviz
Citius Oncology reports 86% response rate in lymphoma study - Investing.com
Citius Oncology, Inc. announces preliminary topline data from its study in high-risk diffuse large B-cell lymphoma patients - Bitget
Citius Oncology Reports Positive LYMPHIR Phase 1 CAR-T Data - TipRanks
Citius Oncology Announces Positive Phase 1 LYMPHIR Data - TipRanks
Citius Oncology (Nasdaq: CTXR) reports encouraging early LYMPHIR CAR-T combo results - Stock Titan
Citius Oncology reports 86% ORR and favorable safety for LYMPHIR prior to commercial CAR‑T in high‑risk DLBCL - TradingView
Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma – Company Announcement - Financial Times
Citius Oncology, Inc. (NASDAQ:CTOR) Short Interest Update - MarketBeat
Citius Oncology Inc Stock (CTOR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.06%
1.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):